Status: Recruiting
Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography
This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.
Participants needed: 150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Trust Bio-sonics, Inc.Updated: Aug 26, 2025Locations: 6
Eligibility criteria
18 years of age or older [+3]
ongoing or recent acute coronary syndrome within 6 months. [+14]